Immuron Limited reported first‑half 2026 revenue of $4.184 million, a 4.8 % year‑over‑year increase, and a half‑year loss per share of AUD 0.007, down from AUD 0.0109 a year earlier. Cash and cash equivalents stood at $10 million, giving the company a 12‑month runway at current burn rates.
The company also announced that the U.S. Food and Drug Administration granted an Investigational New Drug (IND) approval for its lead C. difficile candidate, IMM‑529, on November 5 2025. The approval removes a key regulatory hurdle and positions Immuron to begin Phase 2 trials in the first half of 2026.
Segment‑level data show that sales in Australia reached AUD 3.3 million, up 13 % YoY, while U.S. sales were AUD 0.9 million, up 17 % YoY. Canada experienced an 85 % YoY decline but recovered in the second quarter, contributing to the overall growth.
Management highlighted a strategic focus on partnerships to fund the clinical pipeline and expressed confidence in expanding distribution for its new ProIBS® product. The company’s dual‑engine model—commercial supplements and a biopharmaceutical pipeline—remains a key growth lever.
The revenue increase was driven by stronger demand in core markets, amplified by digital and social media marketing, in‑store promotions, and increased Southeast Asian travel. The narrowing loss per share reflects disciplined cost management amid continued investment in product development.
With a solid cash position and a clear regulatory milestone, Immuron is positioned to advance IMM‑529 while sustaining commercial momentum, though additional funding may be required to support future clinical and commercial expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.